Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies

European Journal of Medicinal Chemistry(2022)10.1016/j.ejmech.2022.114468Source: DataRank Database

Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies is a research paper published in European Journal of Medicinal Chemistry (2022). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.49)OA: greenTopics (54)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Yulong Xu ORCID,Hallie Blevins,Chunqing Guo ORCID,Savannah Biby ORCID,Xiang‐Yang Wang ORCID

Live enrichment

PubMed:35635948 OpenAlex:https://openalex.org/W4281252709

National Institutes of Health

Grant: 5R01AG058673-03

Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease

NIA NIH HHS

Grant: R01 AG058673

NIA NIH HHS

Grant: U01 AG076481

FWCI

1.49

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10084479/pdf/nihms-1882819.pdf

GREENhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10084479/pdf/nihms-1882819.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10084479/pdf/nihms-1882819.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0223523422003701?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0223523422003701?httpAccept=text/plain

Fields of Study

Inflammasome and immune disordersSphingolipid Metabolism and SignalingCholesterol and Lipid MetabolismMedicineChemistry0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsInflammasomesInterleukin-1betaMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinStructure-Activity RelationshipSulfonamides

MeSH Terms

NLR Family, Pyrin Domain-Containing 3 ProteinAnimalsMice, Inbred C57BLStructure-Activity RelationshipSulfonamidesMiceInterleukin-1betaInflammasomes

Keywords

ChemistrySulfonamideLead compoundIn vivoMoietyStructure–activity relationshipSmall moleculeInflammasomeDocking (animal)Combinatorial chemistryPharmacologyComputational biologyBiochemistryIn vitroStereochemistryReceptorMedicineBiologyMice, Inbred C57BLMiceStructure-Activity RelationshipSulfonamidesInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsInterleukin-1βNLRP3PET radiotracerSulfonamide derivatives

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being